Universitätsmedizin Mainz
Universitätsmedizin Mainz
Mainz, Germany11 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The PERSEVERE Study | Embolism, Embolism and Thrombosis, Pulmonary Thromboembolisms, cardiovascular disorder, lung disorder, pulmonary embolism, respiratory system disorder, vascular disorder | Recruiting | Not applicable | 2026-10-08 | NCT06588634 | |
| The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | Chronic Disease, Death, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, cardiovascular disorder, chronic renal failure syndrome, heart disorder, heart failure, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT05374291 | |
| GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG | acute myeloid leukemia, chronic myelomonocytic leukemia, graft versus host disease, immune system disorder, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm | Active, not recruiting | Phase 3 | 2026-08-27 | NCT05153226 | |
| Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 2 | 2026-08-12 | NCT07260175 | |
| A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-08-12 | NCT04307576 | |
| PALbociclib CoLlaborative Adjuvant Study | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-06-15 | NCT02513394 | |
| Prospective Registry for Patients Undergoing Surgery for Male Stress Urinary Incontinence | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urinary Incontinence, Urinary Incontinence, Stress, Urination Disorders, Urogenital Diseases, Urological Manifestations, urinary system disorder | Active, not recruiting | Not stated | 2026-02-02 | NCT02757274 | |
| MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) | Abdominal Neoplasms, Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Peritoneal Diseases, Urogenital Diseases, Urogenital Neoplasms, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, ovarian endometrioid adenocarcinoma, peritoneal neoplasm | Recruiting | Phase 3 | 2025-09-29 | NCT04111978 | |
| tTF-NGR Randomized Study - STS | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, neoplasm, sarcoma | Recruiting | Phase 3 | 2025-04-04 | NCT05597917 | |
| The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 3 | 2025-01-07 | NCT04803994 | |
| OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC | Adnexal Diseases, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Active, not recruiting | Phase 2 | 2024-12-02 | NCT04713514 |